T-cell receptor on MOG-specific cytolytic CD4+ T cells (MOG-specific CD4+ TCR)

The T-cell receptor (TCR) on antigen-specific cytolytic CD4+ T cells recognizing the Myelin Oligodendrocyte Glycoprotein (MOG) presented by MHC Class II molecules is a pivotal driver of neuroinflammation in demyelinating disorders such as Multiple Sclerosis (MS) (Bronge et al., 2022, Nature Communications). Unlike conventional helper CD4+ T cells, this specific subset possesses cytolytic capabilities, allowing them to directly damage oligodendrocytes and the myelin sheath upon recognition of the MOG-MHC II complex (Zaguia et al., 2013, Journal of Immunology). This TCR-antigen interaction is a primary focus for developing antigen-specific therapies that aim to selectively silence or eliminate pathogenic T cells while sparing the rest of the immune system (Cebula et al., 2013, Nature Communications). Therapeutic approaches targeting this receptor include the administration of soluble MOG peptides to induce anergy, the use of tolerogenic dendritic cells, and the development of TCR-specific biologics. Understanding the structural and functional characteristics of this TCR is essential for the design of precision medicines that can halt the progression of autoimmune neurodegeneration.

Other names

MOG-reactive T-cell receptorMyelin oligodendrocyte glycoprotein-specific TCRMOG-MHC II-specific TCRAutoreactive CD4+ T-cell receptor

Antigen-specific immune modulation to induce tolerance, anergy, or deletion of autoreactive T-cell clones.